Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 1.2%

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) traded down 1.2% during trading on Thursday . The stock traded as low as $28.09 and last traded at $29.87. 71,109 shares changed hands during trading, an increase of 42% from the average session volume of 50,104 shares. The stock had previously closed at $30.23.

Neoleukin Therapeutics Stock Performance

The firm’s 50 day simple moving average is $37.24 and its 200 day simple moving average is $25.62. The firm has a market capitalization of $281.56 million, a price-to-earnings ratio of -9.63 and a beta of 1.11.

Institutional Trading of Neoleukin Therapeutics

An institutional investor recently bought a new position in Neoleukin Therapeutics stock. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 310,000 shares of the company’s stock, valued at approximately $1,224,000. Adage Capital Partners GP L.L.C. owned 3.52% of Neoleukin Therapeutics at the end of the most recent quarter. Institutional investors own 52.37% of the company’s stock.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.